Applied DNA Sciences, Inc. has been named a B2i Digital Featured Company as it completes a strategic rebrand reflecting its shift toward a yield-focused BNB digital asset treasury strategy. The company, which trades under the new ticker symbol "BNBX" on NASDAQ, is positioning itself at the intersection of biotechnology and digital asset management while continuing to commercialize its nucleic acid production platforms through its LineaRx subsidiary.
The rebranding represents a fundamental transformation for Applied DNA Sciences, moving beyond its traditional focus on nucleic acid manufacturing to incorporate digital asset management as a core business strategy. This pivot reflects growing corporate interest in digital assets as treasury management tools and signals how traditional companies are adapting to emerging financial technologies. The company previously announced approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, managed through agreements with Cypress LLC and Cypress Management LLC.
David Shapiro, CEO of B2i Digital, stated that Applied DNA's shift toward a BNB-centric digital asset treasury underscores its commitment to innovation in corporate finance and shareholder alignment. "This rebrand signals a strategic move toward greater capital efficiency and digital integration," Shapiro noted through the company's official channels at https://b2idigital.com.
Clay Shorrock, CEO of Applied DNA Sciences, emphasized that partnering with B2i Digital enables the company to share its transformation with a wider investor audience. "As we execute on our BNB treasury strategy, we believe this collaboration will help investors understand how our approach to digital asset management supports both growth and balance-sheet strength," Shorrock explained. The company maintains its investor relations information at https://adnas.com.
The strategic shift maintains Applied DNA's biotechnology foundation while adding digital asset management capabilities. Through LineaRx, the company continues commercializing its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms, which enable cell-free manufacturing of DNA and RNA for therapeutics and diagnostics. This dual approach is designed to generate yield and token accumulation within the Binance ecosystem while maintaining operational technology expertise.
As a B2i Digital Featured Company, Applied DNA will gain access to B2i Digital's network of over 1.4 million investors across multiple platforms including LinkedIn, X, Facebook, Instagram, YouTube, and Stocktwits. The campaign will feature dedicated digital content, investor presentations, and company updates designed to highlight Applied DNA's strategic transformation at scale.
This corporate transformation represents a significant development in how traditional companies are integrating digital assets into their core business strategies. The move from pure biotechnology to a hybrid model incorporating digital asset treasury management could influence other companies considering similar strategic pivots. The company's approach of maintaining its technological foundation while pursuing digital asset yield generation offers a template for how established firms might navigate the transition to incorporating cryptocurrency strategies.
The timing of this rebrand coincides with increasing institutional interest in digital assets as treasury instruments. Applied DNA's strategy of focusing specifically on BNB within the Binance ecosystem represents a targeted approach to digital asset management rather than broad cryptocurrency exposure. This could provide valuable case study data for other companies considering similar treasury strategies in the evolving digital asset landscape.
